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background: Two recent international randomized trials (HORIZONS-AMI and EUROMAX) have compared bivalirudin vs heparin (with or without 
GPI) in STEMI patients undergoing primary PCI.
methods: The pooled analysis was pre-specified in the statistical analysis plan of the EUROMAX trial.  Event proportions were tested using the 
Cochran-Mantel-Haenszel test stratified by study. Heterogeneity between trials was tested with the Breslow-Day test. Follow-up is complete through 
30 days.
results: A total of 5,800 patients were included (2,889 randomized to bivalirudin and 2,911 to heparin with or without GPI). Average age was 61.2 
years, and 23.5% were female. Use of GPI was 8.8% with bivalirudin and 84.8% with heparin. Major 30 day outcomes are presented in the table. 
There was no heterogeneity between the trials for any of the reported endpoints (p>0.10). Bivalirudin was associated with reductions in cardiac 
death, major bleeding, transfusions, thrombocytopenia and net adverse clinical events. There was, however, a higher risk of stent thrombosis, driven 
by an increase in acute stent thrombosis.
Conclusions: The 30-day results of HORIZONS-AMI and EUROMAX are consistent and show significant absolute reductions in cardiac mortality 
(0.9%), major non-CABG-related bleeding (3.6%), transfusions (1.7%), and NACE (3.1%), at the expense of an increase in acute stent thrombosis 
(1.0%). Overall, these results support bivalirudin as the preferred anticoagulation regimen for STEMI patients undergoing primary PCI. 
Bivalirudin no. (%) Heparin ± GPIno. (%) Relative risk (95% CI) P Value
Death 69 (2.4) 90 (3.1) 0.77 (0.57-1.05) 0.10
Cardiac death 59 (2.0) 85 (2.9) 0.70 (0.50-0.97) 0.03
Noncardiac death 10 (0.4) 5 (0.2) 2.01 (0.69-5.88) 0.19
Protocol major bleeding (non-CABG) 120 (4.2) 226 (7.8) 0.53 (0.43-0.66) <0.0001
TIMI bleeding, major (non-CABG) 47 (1.6) 81 (2.8) 0.58 (0.41-0.83) 0.0027
TIMI bleeding, major or minor (non-CABG) 160 (5.5) 281 (9.6) 0.58 (0.48-0.69) <0.0001
Blood transfusion 62 (2.1) 110 (3.8) 0.57 (0.42-0.77) 0.0002
Acquired thrombocytopenia 37 (1.4) 77 (2.9) 0.48 (0.33-0.71) 0.0002
Reinfarction 53 (1.8) 42 (1.4) 1.27 (0.85-1.90) 0.24
Stent thrombosis (ARC) 60 (2.1) 40 (1.4) 1.51 (1.01-2.24) 0.04
Acute (≤24 hours) 36 (1.2) 6 (0.2) 6.04 (2.55-14.31) <0.0001
Subacute (>24 hrs - 30 days) 25 (0.9) 34 (1.2) 0.74 (0.44-1.23) 0.24
Ischemia-driven revascularization 69 (2.4) 52 (1.8) 1.34 (0.94-1.91) 0.11
Any stroke 20 (0.7) 23 (0.8) 0.88 (0.48-1.59) 0.66
MACE 163 (5.6) 161 (5.5) 1.02 (0.83-1.26) 0.85
NACE 253 (8.8) 346 (11.9) 0.74 (0.63-0.86) <0.0001
MACE: Death, reinfarction, ischemia-driven revascularization or stroke ; NACE: Death, reinfarction, ischemia-driven revascularization, stroke, or 
non-CABG major bleeding
